COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.

Ramaswamy, Swathi Beladakere; Govindarajan, Raghav

Ramaswamy, Swathi Beladakere; Govindarajan, Raghav.

Ramaswamy SB; Department of Neurology, University of Missouri, Columbia, Missouri.
Govindarajan R; Department of Neurology, University of Missouri, Columbia, Missouri.

J Neuromuscul Dis ; 7(3): 361-364, 2020.

Article in English | MEDLINE | ID: covidwho-1372059

ABSTRACT

ABSTRACT

This is a brief report of a patient who has refractory Myasthenia Gravis, on multiple long-term immunosuppressive therapies and contracted COVID-19 during this 2020 pandemic. She was quarantined for total of 14 days and recovered successfully without any complications (no myasthenia exacerbation or crisis, no COVID-19 related complications), with no changes to her immunosuppressive therapy. Treatment of MG patients with COVID-19 needs to be tailored to individual patient.

Subject(s)

Betacoronavirus; Coronavirus Infections/complications; Immunosuppressive Agents/therapeutic use; Myasthenia Gravis/drug therapy; Pneumonia, Viral/complications; Adult; COVID-19; Chronic Disease; Female; Humans; Myasthenia Gravis/complications; Pandemics; Precision Medicine/methods; Risk Factors; SARS-CoV-2; Treatment Outcome

Keywords

COVID-19; Plasmapheresis; Refractory Myasthenia Gravis; immunosuppression; outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Immunosuppressive Agents / Myasthenia Gravis Type of study: Case report / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans Language: English Journal: J Neuromuscul Dis Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google